
GRI Stock Forecast & Price Target
GRI Analyst Ratings
Bulls say
GRI Bio Inc's stock outlook is bolstered by its attractive current valuation and significant potential for upside, as reflected in the positive net present value (NPV) analysis despite adjustments to price targets. Recent reports of interim data indicate meaningful improvements in lung function and biomarkers related to fibrosis resolution, underscoring the therapeutic promise of GRI-0621 in treating serious inflammatory and fibrotic diseases. Additionally, the company's commitment to well-tolerated treatment regimens, as evidenced by meeting primary and secondary study endpoints, enhances confidence in the safety and efficacy of its innovative pipeline, further supporting a positive long-term investment perspective.
Bears say
GRI Bio Inc reported a net loss of $3.4 million with an earnings per share (EPS) of $(1.28), which fell short of both internal estimates and consensus expectations. Furthermore, the company's financial performance has shown a pattern of exceeding loss estimates, raising concerns about its ability to achieve profitability in the near term. Key risks identified include balance sheet and liquidity challenges, potential failures in clinical trials, and obstacles in regulatory approval and product commercialization, all of which contribute to a negative outlook on GRI Bio's stock.
This aggregate rating is based on analysts' research of GRI Bio Inc and is not a guaranteed prediction by Public.com or investment advice.
GRI Analyst Forecast & Price Prediction
Start investing in GRI
Order type
Buy in
Order amount
Est. shares
0 shares